Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Soria

Showing results (11-20 of 587) with videos related to

Pageof 59
Sort By:
Pathologie-Biologie|November 1, 1974
[Familial dysfibrinogenemia with abnormal nonomer aggregation. Paris III fibrinogen]J Soria, C Soria
The New England Journal of Medicine|December 26, 2001
Anticoagulation for idiopathic deep-vein thrombosisJ P Kévorkian, C Soria
Bulletin Du Cancer|December 28, 1999
[Evaluation of anticancerous and related drugs: European and American experiences and perspectives]J C Soria, M Marty
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependencyJ Remon, J C Soria
Bulletin Du Cancer|January 22, 1998
[Telomeres, telomerase and cancer]J C Soria, O Rixe
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2016
The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options - an overviewB Solomon, J-C Soria
Bulletin Du Cancer|February 15, 2001
[Telomerase, a universal target in immunotherapy strategies against tumor?]R Rousseau, J C Soria
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 24, 2015
'Statistical controversies in clinical research': a new series in Annals of OncologyJ-C Soria, M Buyse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?J-C Soria, E Deutsch
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Phase I trials in oncology: a new era has startedS Postel-Vinay, J-C Soria
Pageof 59

Showing results (11-20 of 587) with videos related to

Sort By:
Pageof 59
Pathologie-Biologie|November 1, 1974
[Familial dysfibrinogenemia with abnormal nonomer aggregation. Paris III fibrinogen]J Soria, C Soria
The New England Journal of Medicine|December 26, 2001
Anticoagulation for idiopathic deep-vein thrombosisJ P Kévorkian, C Soria
Bulletin Du Cancer|December 28, 1999
[Evaluation of anticancerous and related drugs: European and American experiences and perspectives]J C Soria, M Marty
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependencyJ Remon, J C Soria
Bulletin Du Cancer|January 22, 1998
[Telomeres, telomerase and cancer]J C Soria, O Rixe
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2016
The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options - an overviewB Solomon, J-C Soria
Bulletin Du Cancer|February 15, 2001
[Telomerase, a universal target in immunotherapy strategies against tumor?]R Rousseau, J C Soria
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 24, 2015
'Statistical controversies in clinical research': a new series in Annals of OncologyJ-C Soria, M Buyse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?J-C Soria, E Deutsch
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Phase I trials in oncology: a new era has startedS Postel-Vinay, J-C Soria
Pageof 59